Spruce Biosciences, Inc. (SPRB) — Financial statements
Income statement, balance sheet, and cash flow for Spruce Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 5↓51.3% | 10 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00↓100.0% | 5↓51.3% | 10 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 20↓57.9% | 46↓6.1% | 49↑40.4% | 35↑14.7% | 31 | |
| General & Administrative Expenses | 17↑16.0% | 15↑15.8% | 13↑4.7% | 12↑6.3% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 17↑16.0% | 15↑15.8% | 13↑4.7% | 12↑6.3% | 11 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 37↓40.2% | 61↓1.6% | 62↑31.3% | 47↑12.4% | 42 | |
| Total Costs & Expenses | 37↓40.2% | 61↓1.6% | 62↑31.3% | 47↑12.4% | 42 | |
| Operating Results | ||||||
| Operating Income | -37↑35.0% | -56↓8.0% | -52↓10.0% | -47↓12.4% | -42 | |
| Depreciation & Amortization | 0.02↓54.3% | 0.05↓34.3% | 0.07↓5.4% | 0.07↑8.8% | 0.07 | |
| EBITDA | -39↑26.2% | -53↓11.2% | -47↓3.7% | -46↓9.1% | -42 | |
| EBIT | -39↑26.3% | -53↓11.2% | -47↓3.7% | -46↓9.1% | -42 | |
| Interest & Other Income | ||||||
| Net Interest Income | 1↓66.4% | 3↓23.5% | 4↑269.4% | 1↑588.1% | -0.23 | |
| Interest Income | 1↓66.8% | 3↓24.9% | 5↑199.2% | 2↑1179.8% | 0.12 | |
| Interest Expense | 0.09↓70.7% | 0.31↓36.4% | 0.48↑15.0% | 0.42↑21.7% | 0.35 | |
| Non-Operating Income | 2↑169.1% | -3↑24.9% | -5↓199.2% | -2↓1179.8% | -0.12 | |
| Other Income / Expenses | -2↓178.7% | 3↓23.5% | 4↑269.4% | 1↑588.1% | -0.23 | |
| Income Before Tax | -39↑26.5% | -53↓10.7% | -48↓3.8% | -46↓9.2% | -42 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -39↑26.5% | -53↓10.7% | -48↓3.8% | -46↓9.2% | -42 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -39↑26.5% | -53↓10.7% | -48↓3.8% | -46↓9.2% | -42 | |
| Bottom-Line Net Income | -39↑26.5% | -53↓10.7% | -48↓3.8% | -46↓9.2% | -42 | |
| EPS (Basic) | -50.83↑47.5% | -96.75↓4.0% | -93.00↓29.2% | -72.00↓5.5% | -68.25 | |
| EPS (Diluted) | -50.83↑47.5% | -96.75↓4.0% | -93.00↓29.2% | -72.00↓5.5% | -68.25 | |
| Weighted Average Shares | 0.77↑42.9% | 0.54↑7.2% | 0.50↓18.2% | 0.61↑0.7% | 0.61 | |
| Weighted Average Diluted Shares | 0.77↑42.9% | 0.54↑7.2% | 0.50↓18.2% | 0.61↑0.7% | 0.61 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.